ESC Professional Premium Access

Use of emgliflozine in cardiotoxicity treatment. EMPACARD-treatment registry. Six-months follow-up

Congress Session

About the speaker

Doctor Andres Jose Daniele

Institute of Oncology Angel H. Roffo, Buenos Aires (Argentina)
0 follower

6 more presentations in this session

Basal characteristics of the prospective spanish immunotherapy registry of cardiovascular toxicity: SIR-CVT

Speaker: Doctor E. Zatarain-Nicolas (Madrid, ES)

Thumbnail

The prognostic significance of troponin level in patients with malignancy (NIHR Health Informatics Collaborative TROP-MALIGNANCY study)

Speaker: Doctor A. Kaura (London, GB)

Thumbnail

COVID-19 and acute heart failure among patients with cancer

Speaker: Doctor M. Bergami (Bologna, IT)

Thumbnail

Effect of 1st line treatment on aortic inflammation as assessed by 18 FDG PET/CT in patients with Hodgkin and non-Hodgkin lymphoma

Speaker: Doctor D. Terentes-Printzios (Athens, GR)

Thumbnail

Prognostic impact of coronary artery calcifications in patients with newly diagnosed prostate cancer

Speaker: Doctor N. Stoedkilde-Joergensen (Aarhus, DK)

Thumbnail

Access the full session

Cardio-oncology 4

Speakers: Doctor A. Daniele, Doctor E. Zatarain-Nicolas, Doctor A. Kaura, Doctor M. Bergami, Doctor D. Terentes-Printzios...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk